MedTrace Logo

NGS in Gallbladder Cancer and Response to Treatment

NCT05404347 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-08-13

No results posted yet for this study

Summary

Evidence suggests distinct models of molecular and pathologic progression, and a growing body of genetics data points to a heterogeneous collection of underlying mutations in key oncogenes and tumor suppressor genes. Although tumor genetics have been used to tailor individual treatment regimens and guide clinical decision making in other cancers, these principles have not been applied in gallbladder malignancy. Recent clinical trials with targeted therapies seem promising, although the relationships between subsets of patients with positive responses to therapy and tumor genetics remain unexplored.

Conditions

  • Gallbladder Cancer

Interventions

DIAGNOSTIC_TEST

Next generation sequencing

NGS is carried out on DNA isolated from paraffin embedded tissue

Sponsors & Collaborators

  • Banaras Hindu University

    lead OTHER

Principal Investigators

  • Manoj Pandey, Ms, PhD · Banaras Hindu University

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05404347 on ClinicalTrials.gov